I am still wondering when RVX will get the proper market cap respect for a a small biotech going into  a phase 3/phase 4 NDA enabling study with a BTD and has been deemed safe in all studies done.   You would think this time RVX and a large BP will get it right this time for a successful trial.  I think now they know what endpoints will work and which ones won't. IMO if RVX was trading on the  Nasdaq we would trading be a $500million to 1 Billion USD market , $120 million USD is a joke for this point in RVX trial development